Brief: X4 Pharmaceuticals Announces FDA Acceptance With Priority Review Of U.S. NDA For Mavorixafor In Whim Syndrome

X4 Pharmaceuticals

31/10/2023 12:03

Oct 31 (Reuters) - X4 Pharmaceuticals Inc  XFOR.O :
    * X4 PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE WITH PRIORITY
REVIEW
OF U.S. NDA FOR MAVORIXAFOR IN WHIM SYNDROME
    * X4 PHARMACEUTICALS INC - FDA SETS A PRESCRIPTION DRUG USER
FEE
ACT (PDUFA) TARGET ACTION DATE OF APRIL 30, 2024

Source text for Eikon:  ID:nGNX4TDw0g 
Further company coverage:  XFOR.O